Multi-center observational study to investigate the effect of immune checkpoint inhibitors on MSI-H/dMMR solid tumors

Multi-center observational study on clinicopathological/molecular features and therapeutic effects of immune checkpoint inhibitors in MSI-H/dMMR solid tumors - Multi-center observational study on the immune profiles of MSI-H/dMMR solid tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044728

Enrollment

200

Registered

2021-07-01

Start date

2021-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSI-H/dMMR solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with unresectable or metastatic solid tumors with MSI-H or dMMR diagnosed by PCR/ NGS or IHC methods. 2) Patients with preserved tumor tissue specimens collected between July 2011 and December 2024. 3) Patients who have received or will receive immune checkpoint inhibitors. 4) Patients who have given written consent for this study

Exclusion criteria

Exclusion criteria: 1) patients judged to be inappropriate by a physician in charge 2) Excluded from research subjects when there is a refusal to use samples and information (opt-out) in cases where consent has not been obtained.

Design outcomes

Primary

Measure	Time frame
Evaluation of clinicopathological and molecular biological features related to the efficacy of immune checkpoint inhibitors.	—

Countries

Japan

Contacts

Public ContactKota Itahashi

Research Institute/Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Division of Cancer Immunology

itahashi-tky@umin.org04-7133-1111

Outcome results